CO2023001559A2 - Anticuerpos fgfr3 y métodos de uso - Google Patents

Anticuerpos fgfr3 y métodos de uso

Info

Publication number
CO2023001559A2
CO2023001559A2 CONC2023/0001559A CO2023001559A CO2023001559A2 CO 2023001559 A2 CO2023001559 A2 CO 2023001559A2 CO 2023001559 A CO2023001559 A CO 2023001559A CO 2023001559 A2 CO2023001559 A2 CO 2023001559A2
Authority
CO
Colombia
Prior art keywords
methods
fgfr3
fgfr3 antibodies
antigen binding
antibodies
Prior art date
Application number
CONC2023/0001559A
Other languages
English (en)
Spanish (es)
Inventor
Yves Sabbagh
Yangde Chen
William Brondyk
Huawei Qiu
Sunghae Park
Ronnie Wei
Yu Qiu
Yanfeng Zhou
Cendrine Lemoine
Hyunsuk Cho
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CO2023001559A2 publication Critical patent/CO2023001559A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2023/0001559A 2020-08-21 2023-02-14 Anticuerpos fgfr3 y métodos de uso CO2023001559A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063068575P 2020-08-21 2020-08-21
PCT/US2021/046958 WO2022040560A1 (en) 2020-08-21 2021-08-20 Fgfr3 antibodies and methods of use

Publications (1)

Publication Number Publication Date
CO2023001559A2 true CO2023001559A2 (es) 2023-02-16

Family

ID=77774991

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0001559A CO2023001559A2 (es) 2020-08-21 2023-02-14 Anticuerpos fgfr3 y métodos de uso

Country Status (14)

Country Link
US (2) US11505611B2 (cg-RX-API-DMAC10.html)
EP (1) EP4200019A1 (cg-RX-API-DMAC10.html)
JP (2) JP7858629B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230052963A (cg-RX-API-DMAC10.html)
CN (1) CN116323666A (cg-RX-API-DMAC10.html)
AR (1) AR123306A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021327387A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023002455A2 (cg-RX-API-DMAC10.html)
CA (1) CA3189470A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023001559A2 (cg-RX-API-DMAC10.html)
IL (1) IL300623A (cg-RX-API-DMAC10.html)
MX (1) MX2023002106A (cg-RX-API-DMAC10.html)
TW (1) TW202229343A (cg-RX-API-DMAC10.html)
WO (1) WO2022040560A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
CN120456916A (zh) * 2022-11-14 2025-08-08 瑞泽恩制药公司 抗fgfr3抗体和抗原结合片段及其使用方法
CN121002062A (zh) 2023-01-13 2025-11-21 再生元制药公司 Fgfr3结合分子及其使用方法
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
WO2025207944A1 (en) * 2024-03-29 2025-10-02 Sidewinder Therapeutics, Inc. Fgfr3-iiib-binding antibodies
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000916A2 (en) 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
DK0646182T3 (da) 1992-06-18 1996-09-16 Whittier Inst Diabetes & Endoc Fremgangsmåde til påvisning af neoplastiske sygdomme
AU6446194A (en) 1993-03-17 1994-10-11 Whittier Institute For Diabetes And Endocrinology, The Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20030143676A1 (en) 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
EP1208231B2 (en) 1999-05-05 2009-12-30 Institut Curie Means for detecting and treating pathologies linked to fgfr3
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
AU7764200A (en) 1999-10-06 2001-05-10 Tigenix N.V. In vivo assay and molecular markers for testing the phenotypic stability of cellpopulations, and selecting cell populations for autologous transplantation
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
ES2363765T3 (es) 2002-01-31 2011-08-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Agonistas de fgfr.
NZ537208A (en) 2002-06-27 2009-02-28 Adipogen Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
AU2003265057A1 (en) 2002-09-04 2004-03-29 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
CA2510715A1 (en) 2002-12-20 2004-07-08 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
US8124331B2 (en) 2003-03-26 2012-02-28 Progenika Biopharma, S.A. In vitro method to detect bladder transitional cell carcinoma
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
WO2005066211A2 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
EP1544213B1 (en) 2003-12-19 2008-02-20 Charité - Universitätsmedizin Berlin Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases
AU2005216547B2 (en) 2004-02-24 2009-03-12 Allergan, Inc. Botulinum toxin screening assays
EP1773305A2 (en) 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
AU2005302083A1 (en) 2004-11-04 2006-05-11 Fibron Limited Treatment of B-cell malignancies
EP1659175A1 (en) 2004-11-18 2006-05-24 Institut Curie Alterations in seborrheic keratoses and their applications
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
EP1861419B1 (en) 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009511613A (ja) 2005-10-17 2009-03-19 エンカム ファーマシューティカルズ アクティーゼルスカブ 神経細胞接着分子l1のペプチド断片を含む新規fgf受容体結合化合物
WO2007067968A2 (en) 2005-12-08 2007-06-14 Novartis Ag Effects of inhibitors of fgfr3 on gene transcription
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
WO2008127707A1 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
ES2553390T3 (es) 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
WO2009146033A2 (en) 2008-03-31 2009-12-03 Sma Foundation Compositions and methods for modulating smn activity
KR101590495B1 (ko) 2008-05-29 2016-02-01 갤럭시 바이오테크, 엘엘씨 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
ES2549769T3 (es) 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
WO2011088196A2 (en) 2010-01-14 2011-07-21 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
KR20220017512A (ko) 2012-03-08 2022-02-11 아스테라스 세이야쿠 가부시키가이샤 신규 fgfr3 융합체
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20150292030A1 (en) 2012-11-27 2015-10-15 Board Of Regents, The University Of Texas System Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer
CN105209607B (zh) 2013-04-05 2020-02-07 大学健康网络 产生软骨细胞谱系细胞和/或类软骨组织的方法和组合物
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法
SG11201706727XA (en) 2015-02-19 2017-09-28 Bioclin Therapeutics Inc Methods, compositions, and kits for treatment of cancer
CN110785184A (zh) 2017-02-06 2020-02-11 雷尼尔医疗公司 用于治疗癌症的方法,组合物和试剂盒

Also Published As

Publication number Publication date
JP2026126325A (ja) 2026-08-04
US20220056142A1 (en) 2022-02-24
JP7858629B2 (ja) 2026-05-14
EP4200019A1 (en) 2023-06-28
BR112023002455A2 (pt) 2023-03-28
CN116323666A (zh) 2023-06-23
IL300623A (en) 2023-04-01
WO2022040560A1 (en) 2022-02-24
AU2021327387A1 (en) 2023-05-04
AU2021327387A9 (en) 2023-07-06
TW202229343A (zh) 2022-08-01
JP2023538098A (ja) 2023-09-06
KR20230052963A (ko) 2023-04-20
MX2023002106A (es) 2023-03-15
AR123306A1 (es) 2022-11-16
CA3189470A1 (en) 2022-02-24
US20230303704A1 (en) 2023-09-28
US11505611B2 (en) 2022-11-22

Similar Documents

Publication Publication Date Title
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112022014623A2 (pt) Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
AR115418A1 (es) ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
CO2022002001A2 (es) Usos terapéuticos de anticuerpos anti-variable delta 1 de tcr
BR112023002455A2 (pt) Anticorpos fgfr3 e métodos de uso
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
JOP20170041B1 (ar) اجسام مضادة ضد vista (b7h5)
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
MX2021009975A (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer.
AR115257A1 (es) Anticuerpos de fijación a bcma y sus usos
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
CR20110118A (es) Tratamiento de enfermedades autoinmunes e inflamatorias
ECSP077222A (es) Anticuerpos monoclonales humanos contra interleucina-4 humana (il-4)
MX2024009860A (es) Anticuerpos monoclonales humanos que se dirigen ampliamente a los coronavirus
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
MX2024005705A (es) Composiciones de liquidos ionicos.
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
EA202092593A1 (ru) Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение
CO2025009742A2 (es) Tratamiento de la enfermedad autoinmunitaria
JOP20240161A1 (ar) طرق لعلاج الخاضعين المصابين بالصدفية اللويحية لفروة الرأس
CO2022019225A2 (es) Anticuerpos anti-hbv y métodos de uso
MX2024012582A (es) Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso
MX2022001626A (es) Composiciones biofarmaceuticas y procedimientos conexos.